A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis
| Autor: | Nancy J. Olsen, Christopher G. Jackson, David A. Fox, Todd J. Lorenz, Raye H. Brooks, Kenneth N. Gold, Grant W. Cannon, Betty Nelson, John J. Cush, Steven B. Abramson, Thomas A. Medsger, Grace P. Teal, Jacques Caldwell, W. Joseph McCune, S Lee, Peter E. Lipsky, Leonard H. Calabrese, Vibeke Strand, Eric L. Matteson, James Gruber, Micheal Weisman, Luis R. Espinoza, E. William St. Clair |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
medicine.medical_specialty
Immunology Placebo-controlled study Arthritis chemical and pharmacologic phenomena Placebo Gastroenterology law.invention Rheumatology Randomized controlled trial immune system diseases law hemic and lymphatic diseases Internal medicine medicine Immunology and Allergy Pharmacology (medical) Adverse effect business.industry hemic and immune systems medicine.disease Surgery Immunoconjugate Clinical trial Rheumatoid arthritis business |
| Zdroj: | Arthritis & Rheumatism. 39:1102-1108 |
| ISSN: | 1529-0131 0004-3591 |
| DOI: | 10.1002/art.1780390705 |
| Popis: | Objective. To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CD5-IC. Results. Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated. Conclusion. At the doses used in this study, CD5-IC was ineffective for treating RA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text